Literature DB >> 7217960

Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.

N Hassan, D L McLellan.   

Abstract

Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days. Passive stretch responses were measured before administration and for four hours afterwards. DS103-282 was more effective than baclofen, and both drugs were more effective than placebo. Analysis of the recordings confirmed that DS103-282 had a specific effect upon stretch reflexes independent of its effect on resting muscle tone. Its action appeared at 30 to 45 minutes after ingestion, with maximum activity at 60-90 minutes. Unwanted effects of DS103-282 were drowsiness and (in one case) potentiation of antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7217960      PMCID: PMC490787          DOI: 10.1136/jnnp.43.12.1132

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  3 in total

1.  [Clinical experiences with a new muscle relaxant (DS 103-282 Sandoz) (author's transl)].

Authors:  E Ringwald; S J Campean; F Gerstenbrand; A Lorincz; P Lörincz; H P Ludin
Journal:  Nervenarzt       Date:  1977-07       Impact factor: 1.214

2.  Time course of clinical and physiological effects of stimulation of the cerebellar surface in patients with spasticity.

Authors:  D L McLellan; M Selwyn; I S Cooper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-02       Impact factor: 10.154

3.  The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent.

Authors:  A C Sayers; H R Bürki; E Eichenberger
Journal:  Arzneimittelforschung       Date:  1980
  3 in total
  9 in total

1.  The effect of intrathecal baclofen on electrical muscle activity in spasticity.

Authors:  H Müller; J Zierski; D Dralle; U Börner; O Hoffmann
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

2.  The assessment of drug treatment of spastic gait.

Authors:  R N Corston; F Johnson; R B Godwin-Austen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-11       Impact factor: 10.154

3.  Potent suppression of stretch reflex activity after systemic or spinal delivery of tizanidine in rats with spinal ischemia-induced chronic spastic paraplegia.

Authors:  T Fuchigami; O Kakinohana; M P Hefferan; N Lukacova; S Marsala; O Platoshyn; K Sugahara; T L Yaksh; M Marsala
Journal:  Neuroscience       Date:  2011-08-16       Impact factor: 3.590

Review 4.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

5.  Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).

Authors:  M Emre; G C Leslie; C Muir; N J Part; R Pokorny; R C Roberts
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

6.  Tizanidine--initial pharmacokinetic studies in patients with spasticity.

Authors:  V Heazlewood; P Symoniw; P Maruff; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282).

Authors:  J Davies
Journal:  Br J Pharmacol       Date:  1982-07       Impact factor: 8.739

8.  Action of tizanidine on responses of forearm flexors and extensors to torque disturbances.

Authors:  R Mackel; E E Brink; Y Nakajima
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

9.  Tizanidine in the treatment of spasticity.

Authors:  P M Newman; M Nogues; P K Newman; D Weightman; P Hudgson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.